In the News

1935 News Items found
MSK immunotherapy drug development expert Dr. David Scheinberg
Article
A cancer vaccine significantly improved survival for certain patients with acute myeloid leukemia (AML) in a clinical trial.
Detail of pipetting
MSK Research Highlights, November 16, 2026
New MSK research shows how BRCA2-mutant cancers rely on a previously unknown DNA repair lifeline; helps explain the effectiveness of cyclophosphamide, a drug used in bone marrow transplants; and finds small cell transformation persists despite early chemotherapy in high-risk EGFR-mutant lung cancer.
Memorial Sloan Kettering computation biologists Dr. Sohrab Shah (left) and Dr. Ben Greenbaum
Article
Learn about research that could improve the prediction of T cell responses to immunotherapies.
Dr. Rosa Nouvini seen smiling outdoors.
Learn from an MSK expert about screening in the Latino community for colorectal cancer, to help prevent the disease.
MSK thoracic oncologist Kathryn Arbour, MD, seen smiling.
Learn how MSK doctors are treating lung cancer in clinical trials with daraxonrasib, which targets RAS mutations in tumors.
Colorectal Surgeon Dr. Julio Garcia-Aguilar seen smiling in office.
Learn about the latest treatments for colon and rectal (colorectal) cancer at Memorial Sloan Kettering Cancer Center.
Christina Leslie
Dr. Christina Leslie’s work sits at the crossroads of two technological revolutions: single-cell genomics and artificial intelligence. We sat down with Dr. Leslie to discuss the promise — and limitations — of this technological frontier, and what it means for cancer research.
Four people treated for rectal cancer in a clinical trial at MSK are seen outdoors with the trial’s two principal investigators.
The FDA approved a treatment for rectal cancer tumors with a specific genetic signature that uses only the immunotherapy Jemperli, allowing some patients to be successfully treated without surgery, radiation, or chemotherapy.
Beth and Mark Ryzyk stand on a long bridge
New results from a cancer vaccine designed to prevent melanoma from returning after surgery showed positive results, according to a phase 3 clinical trial.
Memorial Sloan Kettering medical oncologist Eileen O'Reilly
Read about a therapeutic vaccine that could potentially prevent certain pancreatic cancers from returning.